Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 8/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804971 | 0.90 | QDPR (0.57) | QDPRHTR2CSIGMAR1 | |
| SCHEMBL6584726 | 0.88 | QDPR (0.46) | QDPRHTR2CSIGMAR1HTR6KDM4E | |
| SCHEMBL5090686 | 0.75 | QDPR (0.48) | QDPRHTR2CSIGMAR1 | |
| SCHEMBL9618220 | 0.75 | ACMSD (0.45) | NISCHKDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL7065679 | 0.74 | CHRM3 (0.40) | HTR2CSIGMAR1NISCH | |
| SCHEMBL31367896 | 0.72 | QDPR (1.00) | QDPRHTR2CSIGMAR1 | |
| SCHEMBL3383939 | 0.72 | HTR2C (0.62) | QDPRHTR2CSIGMAR1HTR6 | |
| SCHEMBL14956908 | 0.72 | QDPR (0.60) | QDPRHTR2CSIGMAR1HTR6 | |
| SCHEMBL7744628 | 0.72 | QDPR (1.00) | QDPRHTR2CSIGMAR1 | |
| SCHEMBL3385014 | 0.72 | SIGMAR1 (0.68) | QDPRHTR2CSIGMAR1HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742047-B1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-05-12 | — | — | EP | disclosed |
| EP-2882739-B1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-05-03 | — | — | EP | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| US-9598407-B2 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2017-03-21 | — | — | US | disclosed |
| US-9296760-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-29 | — | — | US | disclosed |
| US-9296760-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-29 | — | — | US | disclosed |
| US-20150225424-A1 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225424-A1 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | US | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-11 | — | — | US | disclosed |
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | JANSSEN SCIENCES IRELAND UC (IE) | 2014-06-12 | — | — | US | disclosed |
| WO-2014023815-A1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013021052-A1 | ANTIBACTERIAL PIPERIDINYL SUBSTITUTED 3,4-DIHYDRO-1H-[1,8]NAPHTHYRIDINONES | JANSSEN R&D IRELAND (IE) | 2013-02-14 | — | — | WO | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163038-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | FAR1, DNASE1, LAMP1 | QDPR 31/4885HTR2C 4722/4885SIGMAR1 971/4885 |
| US-20150225424-A1 | Antibacterial compounds | FAR1, GAA, ECI1 | QDPR 189/4885HTR2C 4872/4885SIGMAR1 2704/4885 |
| US-20150158866-A1 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones | NQO2, ALPI, ECI1 | QDPR 11/4885HTR2C 4634/4885SIGMAR1 1357/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | QDPR 405/4885HTR2C 2451/4885SIGMAR1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.